Drug intelligence / Profile preview

IL-MTM

Development stage: Preclinical
Lead developer: PARAS Biopharma
Modality: Recombinant Proteins and Enzymes

Overview

IL-MTM (also known as PB(CT)-4040) is a recombinant protein biobetter developed by Paras Biopharmaceuticals. It is designed to target the Interleukin-1 receptor (IL-1R), functioning as an antagonist to block the inflammatory signaling pathways mediated by IL-1 cytokines. As a biobetter, it is engineered to provide enhanced therapeutic efficacy or improved pharmacokinetic properties compared to first-generation IL-1R antagonists like anakinra. The candidate is currently in the preclinical stage of development for various novel therapeutic applications that have not been specifically disclosed by the developer.

Brand names: IL-MTM
Other names: PB(CT)-4040

Targets

IL1R1 (Interleukin-1 Receptor Type 1)

Beyond the preview

Go deeper on IL-MTM.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IL-MTM.

Explore the full profile